Quest said that while it will continue to look at acquisition opportunities, it plans to focus on integrating and driving productivity of recently purchased assets.

Revenues for the three months ended Dec. 31 were $2.62 billion, up from $2.29 billion in Q4 2023 and above the consensus Wall Street estimate of $2.58 billion.

While Roche saw a 1 percent decline in full-year 2024 diagnostics sales year over year, the base business within the division rose 8 percent. Overall, Roche reported ...

The QuickFinder COVID-19/Flu Antigen Self-Test and the QuickFinder COVID-19/Flu Antigen Pro Test detect SARS-CoV-2, influenza A, and influenza B in swab specimens and provide results within 15 minutes ...

Medix said the acquisition adds to its portfolio of raw materials used for in vitro diagnostics development and improves its ability to support immunoassay developers.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

The partners plan to expand testing for early detection of childhood leukemias and lymphomas, bolster local testing capacity, and conduct a research study.

NEW YORK – Guardant Health announced Tuesday that its Guardant Reveal liquid biopsy test has received coverage from Medicare administrative contractor Palmetto GBA to monitor colorectal cancer ...

The Amsterdam-based biotech firm said that its melt curve analysis-based test is used as a first-tier genetic screening tool to aid the diagnosis of SMA.

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

The government alleges that BioReference submitted claims to federal healthcare programs for blood tests that were not ordered by a patient's provider.

The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.